Upload
mahina
View
16
Download
0
Embed Size (px)
DESCRIPTION
Planning the Lifecycle of Safety Evaluation. Brenda Crowe, PhD Eli Lilly and Company. Conference Program Committee. Brenda Crowe, PhD, Lilly (Co-chair) Wanju Dai, MD, DrPH, sanofi-aventis (Co-chair) Gerald Dal Pan, MD, MHS, FDA Henry “Skip” Francis, MD, FDA - PowerPoint PPT Presentation
Citation preview
www.diahome.org
Planning the Lifecycle of Safety Evaluation
Brenda Crowe, PhD
Eli Lilly and Company
www.diahome.org
Conference Program Committee
• Brenda Crowe, PhD, Lilly (Co-chair)• Wanju Dai, MD, DrPH, sanofi-aventis (Co-chair)• Gerald Dal Pan, MD, MHS, FDA• Henry “Skip” Francis, MD, FDA• Paul Huckle, MD, GlaxoSmithKline• Robert O’Neill, PhD, FDA• Manfred Oster, MD, sanofi-aventis• George Rochester, PhD, RAC, FDA• Amy Xia, PhD, Amgen
Program Advisors• Walt Offen, PhD, Lilly• Steve Snapinn, PhD, Lilly
www.diahome.org
Conference Co-chairpersons
In addition to the program committee:• Howard Chazin, MD, MBA, FDA• Eileen King, PhD, Procter & Gamble• Judith Racoosin, MD, MPH, FDA• James Hung, PhD, FDA• Henry Hsu, PhD, MPH, FDA• Jesse Berlin, ScD, Johnson & Johnson• Sandra Kweder, MD, FDA
www.diahome.org
Special Thanks
• Constance Burnett, DIA
• Jessica Kusma, DIA
• Debra Michaels, DIA
www.diahome.org
Conference Goals
• Stimulate discussion among FDA and industry participants regarding proactive planning of safety evaluation throughout the lifecycle of drug development.– Includes planning for data collection,
evaluation (including data monitoring committees), integration, analysis (including meta-analysis) and reporting.
www.diahome.org
Program Outline—Day 1
• 9:10 – 10:30: Challenges and Opportunities to Improve Premarketing Safety Planning, Evaluation and Reporting
• 11:00 – noon, 1:30 – 2:30: Combining Safety Data at a Development Program Level—Data Collection and Study Design: Dirt Road Vs. Super Highway
• 2:30 – 3:45: How to Improve Safety Data Analysis and Presentation
• 4:15 – 5:30: Safety Boundaries for Data Monitoring Committees
• 5:30 - 6:30: Reception
www.diahome.org
Program Outline—Day 2
• 8:30 – 8:40: Welcome and Keynote Introduction• 8:40 – 9:30: Keynote Presentation (Janet Woodcock)• 9:30 – 10:30: Introduction and Overview of Meta-
analysis• 11:00 – 12:30: Concurrent sessions (Meta-analysis
of 1. Rare Events and 2. Observational Data)• 1:45 – 3:00: Regulatory Decision Making Based on
Meta-analysis Results• 3:30 – 4:30: Lessons Learned and Path Forward
Panel• 4:35: Conference adjourned
www.diahome.org
Time• Session chairs:
Please synchronize your watches:It is now: ….9:0X am
• Very important: We need to stick to allotted time
www.diahome.org
5minute
www.diahome.org
1minute
www.diahome.org
0minute
www.diahome.org
-1minute
Stop Now!! Please
You’re killing me!